Keratinocyte proliferation promoter and hair growth-related factor regulator
Diphenhydramine, glycyrrhetinic acids, and hinokitiol enhance minoxidil's hair growth effects by promoting conversion to minoxidil sulfate and regulating key hair growth factors, addressing the limitations of existing minoxidil formulations.
Patent Information
- Application Number
- JP2020026085
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-02-19
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-02-19
AI Technical Summary
Existing minoxidil formulations do not fully express their hair growth potential due to insufficient conversion to the more active form, minoxidil sulfate, and lack effective promoters for keratinocyte proliferation and regulators of hair growth-related factors.
The use of diphenhydramine, glycyrrhetinic acids, and hinokitiol as active ingredients to promote the conversion of minoxidil to minoxidil sulfate, enhance keratinocyte proliferation, and regulate various hair growth-related factors by influencing SULT1A1 production and signaling pathways such as BMP, WNT, and FGF.
Enhances hair growth effects on minoxidil non-responders and promotes hair restoration, prevention of gray hair, and overall hair health through direct activation of keratinocytes and modulation of key growth factors.
Smart Images

Figure 0007578900000002 
Figure 0007578900000003 
Figure 0007578900000004
Abstract
Description
[Technical field]
[0001] The present invention relates to a metabolic activator of minoxidil, a keratinocyte proliferation promoter, and a hair growth-related factor regulator. [Background technology]
[0002] Hair follicles are mainly composed of epithelial cells derived from the ectoderm and mesenchymal cells derived from the mesoderm, and their development and regeneration occur through the interaction of these cells. Hair follicles are organs that repeat the process of regeneration and regression, called the hair cycle, throughout life. The activation of dormant hair follicle stem cells initiates the anagen phase. During the anagen phase, the production of growth factors (VEGF, HGF, IGF-1, FGF7, Wnt, Noggin, etc.) that act as hair growth signals from mesenchymal hair papilla cells and epithelial cells becomes active, and the division of epithelial cells such as hair matrix cells, which are the material for hair (hair shaft), becomes active, causing hair to elongate. At the end of the anagen phase, the production of growth factors (BMP, TGF-β, etc.) that act as hair loss signals becomes active from mesenchymal cells such as the hair papilla and subcutaneous fat, causing the hair follicle to transition to the catagen phase. During the catagen phase, the hair matrix stops cell division and the number of cells decreases due to apoptosis. After that, the hair follicle transitions to the telogen phase and then to the anagen phase again (Non-Patent Document 1). In other words, in order to promote hair growth, it is important to directly activate the proliferation of epithelial cells (keratinocytes) in the hair follicle, which are the material for hair, to increase the production of growth factors that act as hair growth signals, or to decrease the production of growth factors that act as hair loss signals, thereby inducing and maintaining the anagen phase of the hair follicle.
[0003] Minoxidil is a hair growth component used to treat various types of alopecia, including male pattern baldness. Minoxidil itself is active, but it is metabolized by sulfotransferase present mainly in epithelial cells of hair follicles, especially in the lower outer root sheath cells, and converted to the sulfated form minoxidil sulfate (Non-Patent Document 2). Minoxidil sulfate is more active against hair follicles than minoxidil, and is therefore considered to be the active form of minoxidil (Non-Patent Document 3). There are multiple subtypes of sulfotransferase, and it has been revealed that SULT1A1 is largely involved in the conversion of minoxidil in hair tissue, and its activity correlates with the therapeutic effect of minoxidil on alopecia (Non-Patent Documents 4, 5). Minoxidil and minoxidil sulfate act on sulfonylurea receptors (SUR) present in the cell membrane of hair papilla cells and on SUR present in the mitochondria of various cells, thereby opening KATP channels, enhancing the production of hair growth signals, activating cell proliferation, inhibiting cell death, and promoting hair growth (Non-Patent Document 6). In other words, by locally increasing the amount and activity of SULT1A1 in hair follicle tissue and increasing the amount of the receptor SUR, it is possible to improve the hair growth effect of minoxidil without increasing systemic side effects, and it is possible to exert a therapeutic effect on so-called minoxidil non-responders (people for whom the alopecia treatment effect of minoxidil is not fully observed). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2016-121134 A [Patent Document 2] JP 2007-022919 A [Non-patent literature]
[0005] [Non-Patent Document 1] "Anti-aging Series 1: The Actual Situation of Gray Hair, Hair Loss, and Hair Growth" by Seiji Arase et al., NTS, July 4, 2005, pp.1-34,65-77 [Non-Patent Document 2] Dooley TP, Walker CJ, Hirshey SJ, Falany CN, Diani AR, Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles, J Invest Dermatol. 1991;96(1):65-70. [Non-Patent Document 3] Buhl AE, Waldon DJ, Baker CA, Johnson GA, Minoxidil sulfate is the active metabolite that stimulates hair follicles, J Invest Dermatol. 1990;95(5):553-7. [Non-Patent Document 4] Goren A, Castano JA, McCoy J, Bermudez F, Lotti T, Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia, Dermatol Ther. 2014;27(3):171-3. [Non-Patent Document 5] Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME, Human sulfotransferases and their role in chemical metabolism, Toxicol Sci. 2006;90(1):5-22. [Non-Patent Document 6] Susumu Kotomo, Hair growth effect of minoxidil, Japanese Pharmacology Journal. 2002;119,167-174.
Direct Environment 7
Outdoor Track 8
Outdoor Tools9
Outdoor Tools 10
Outdoor Content11
[0006] The object of the present invention is to provide a metabolic activator of minoxidil that improves conditions in which the hair growth effect of minoxidil is not fully manifested by promoting the conversion of minoxidil to minoxidil sulfate, a more strongly active form, in the living body, and to provide a keratinocyte proliferation activator and a hair growth-related factor regulator that promote hair growth. [Means for solving the problem]
[0007] As a result of extensive research, the inventors have discovered that diphenhydramine, glycyrrhetinic acids and hinokitiol have the effect of promoting the conversion of minoxidil to the more active form minoxidil sulfate by promoting the production of the sulfotransferase SULT1A1, and further have the effect of directly activating the proliferation of keratinocytes and controlling various hair growth-related factors, thereby completing the present invention.
[0008] That is, the present invention provides (1) A metabolic activator of minoxidil, comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol; (2) The metabolic activator of minoxidil according to (1), which is based on the effect of promoting the conversion to minoxidil sulfate. (3) The metabolic activator of minoxidil according to (1), which is based on the effect of promoting the production of sulfotransferase. (4) The metabolic activator of minoxidil according to (1), which is based on the effect of promoting the production of SULT1A1. (5) A keratinocyte proliferation promoter comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol. (6) An inhibitor of BMP signaling, comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol. (7) The BMP signal inhibitor according to (6), wherein the active ingredient is at least one selected from the group consisting of diphenhydramine or a salt thereof and glycyrrhetinic acids, and is based on the FST production promoting effect. (8) The BMP signal inhibitor according to (6), wherein the active ingredient is hinokitiol and is based on the effect of promoting the production of NOG. (9) The BMP signal inhibitor according to (6), wherein the active ingredient is at least one selected from the group consisting of glycyrrhetinic acids and hinokitiol, and the inhibitory effect is based on the BMP2 production inhibitory effect. (10) A WNT signal activator comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol. (11) The WNT signal activator according to (10), wherein the active ingredient is at least one selected from the group consisting of glycyrrhetinic acids and hinokitiol, and is based on the effect of promoting the production of LEF1. (12) The WNT signal activator according to (10), wherein the active ingredient is at least one selected from the group consisting of glycyrrhetinic acids and hinokitiol, and is based on the effect of promoting the production of AXIN2. (13) The WNT signal activator according to (10), wherein the active ingredient is at least one selected from the group consisting of diphenhydramine or a salt thereof and hinokitiol, and the active ingredient is based on an inhibitory effect on the production of DKK1. (14) An agent for promoting the production of FGF2, comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol. (15) An agent for promoting the production of FGF7, comprising at least one active ingredient selected from the group consisting of glycyrrhetinic acids and hinokitiol. (16) An agent for promoting the expression of VEGFA, comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof and hinokitiol. (17) A VCAN production promoter comprising at least one active ingredient selected from the group consisting of glycyrrhetinic acids and hinokitiol. (18) A KITL production promoter comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol. (19) A COL17A1 production promoter comprising at least one active ingredient selected from the group consisting of diphenhydramine or a salt thereof, and hinokitiol. It is. Effect of the Invention
[0009] The minoxidil metabolic activator of the present invention can promote hair growth even in minoxidil non-responders by promoting the conversion of minoxidil to minoxidil sulfate, which is a stronger active substance. In addition, the keratinocyte proliferation promoter and each hair growth-related factor regulator of the present invention can provide excellent effects in hair growth, hair growth, prevention and improvement of gray hair, etc. through various mechanisms by applying them to hair. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a graph showing the results of evaluation of the effect of each compound on keratinocyte proliferation in Test Example 1. [Diagram 2] FIG. 2 is a graph showing the results of evaluating the effect of each compound on SULT1A1 expression in keratinocytes in Test Example 2. [Diagram 3] FIG. 3 is a graph showing the results of evaluating the effect of each compound on FST expression in keratinocytes in Test Example 2. [Figure 4] FIG. 4 is a graph showing the results of evaluating the effect of each compound on LEF1 expression in keratinocytes in Test Example 2. [Diagram 5] FIG. 5 is a graph showing the results of evaluating the effect of each compound on AXIN2 expression in keratinocytes in Test Example 2. [Figure 6] FIG. 6 is a graph showing the results of evaluating the effect of each compound on FGF2 expression in keratinocytes in Test Example 2. [Figure 7] FIG. 7 is a graph showing the results of evaluating the effect of each compound on KITL expression in keratinocytes in Test Example 2. [Figure 8] FIG. 8 is a graph showing the results of evaluating the effect of each compound on COL17A1 expression in keratinocytes in Test Example 2. [Figure 9] FIG. 9 is a graph showing the results of evaluating the effect of each compound on NOG expression in hair papilla cells in Test Example 3. [Figure 10] FIG. 10 is a graph showing the results of evaluating the effect of each compound on BMP2 expression in hair papilla cells in Test Example 3. [Figure 11] FIG. 11 is a graph showing the results of evaluating the effect of each compound on FGF2 expression in hair papilla cells in Test Example 3. [Figure 12] FIG. 12 is a graph showing the results of evaluating the effect of each compound on FGF7 expression in hair papilla cells in Test Example 3. [Figure 13] FIG. 13 is a graph showing the results of evaluating the effect of each compound on VEGFA expression in hair papilla cells in Test Example 3. [Figure 14] FIG. 14 is a graph showing the results of evaluating the effect of each compound on VCAN expression in hair papilla cells in Test Example 3. [Figure 15] FIG. 15 is a graph showing the results of evaluating the effect of each compound on DKK1 expression in hair papilla cells in Test Example 3. [Figure 16] FIG. 16 is a graph showing the results of evaluating the effect of each compound on DKK1 expression in hair papilla cells in Test Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] In the present invention, diphenhydramine or a salt thereof, glycyrrhetinic acids and hinokitiol are used as active ingredients. These compounds can be produced by known synthesis methods, and commercially available products may also be used.
[0012] Diphenhydramine is a compound represented by 2-diphenylmethoxy-N,N-dimethylethylamine. The salt of diphenhydramine is not particularly limited as long as it is pharma- ceutically acceptable, and examples thereof include hydrochloride, sulfate, and nitrate. Among these, the hydrochloride form (diphenhydramine hydrochloride, diphenhydramine hydrochloride) is preferred.
[0013] In the present invention, glycyrrhetinic acids include glycyrrhetinic acid, which is a compound represented by 3β-hydroxy-11-oxoolean-12-en-30-acid, its derivatives, and their salts. Glycyrrhetinic acid is a compound obtained by hydrolysis of glycyrrhizinic acid obtained from licorice, and glycyrrhetinic acids also include licorice and its extracts, hydrolysates, and other non-purified products. Specific examples of glycyrrhetinic acids include glycyrrhizinic acid, dipotassium glycyrrhizinate, stearyl glycyrrhetinate, and disodium succinylglycyrrhetinate, and one or more of these can be used.
[0014] Hinokitiol is a compound represented by 2-hydroxy-4-isopropylcyclohepta-2,4,6-trien-1-one. Since hinokitiol is a compound contained in plants such as cedar and Japanese cypress, non-purified products such as extracts of these plants may be used. It may also be a pharmaceutically acceptable salt.
[0015] The above diphenhydramine or its salt, glycyrrhetinic acid and hinokitiol have an action of activating metabolism of minoxidil in the living body. Minoxidil is a compound represented by 6-piperidin-1-ylpyrimidine-2,4-diamine-3-oxide or 2,6-diamino-4-piperidinopyrimidine 1-oxide, and minoxidil sulfate is its sulfate salt, and is called minoxidil sulfate, minoxidil sulfate, active minoxidil, etc. In hair follicles, minoxidil is sulfated by the action of sulfotransferase and converted to minoxidil sulfate. Sulfotransferase is a kind of drug metabolizing enzyme, and catalyzes the transfer reaction of sulfuryl group, that is, sulfate conjugation, and is also called sulfate (group) transferase. One type of sulfotransferase is SULT1A1 (sulfotransferase 1A1), which is responsible for converting minoxidil to minoxidil sulfate in hair follicles. In the minoxidil metabolic activator of the present invention, the active ingredients diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol have a production promoting effect of SULT1A1, and therefore promote the conversion of minoxidil to minoxidil sulfate, activating minoxidil.
[0016] In addition, the above diphenhydramine or its salts, glycyrrhetinic acids, and hinokitiol have the effect of promoting keratinocyte proliferation, as well as controlling hair growth-related factors. Keratinocytes are a general term for epithelial cells that make up hair follicles and skin tissues. Hair growth is promoted by directly activating the proliferation of keratinocytes in hair follicles, or by activating growth factors (VEGF, HGF, IGF-1, FGF7, Wnt, Noggin, etc.) that are hair growth signals, or by suppressing growth factors (BMP, TGF-β, etc.) that are hair loss signals, thereby inducing and maintaining the anagen phase of hair follicles.
[0017] It has been elucidated that BMP signaling is involved in maintaining the dormant state of hair follicle stem cells in hair follicles. BMP signaling is an in vivo signaling by the bone morphogenetic protein (BMP) group, which is a secreted protein, and is known to play an important role in various aspects such as embryonic development. When the ligand BMP binds to the BMP receptor on the cell membrane, the signal is transmitted into the cell via Smad and regulates the transcription of various target genes. During the resting phase, the dormant state of hair follicle stem cells is maintained by BMP produced by the hair follicle stem cells themselves and mesenchymal cells (dermal papilla cells, fibroblasts, and subcutaneous adipocytes).
[0018] On the other hand, it has been elucidated that WNT signaling is involved in the activation of hair follicle stem cells. WNT signaling is an in vivo signaling pathway mediated by the WNT family of secreted proteins, and is known to play an important role in a wide variety of biological processes during development. It is activated when the ligand WNT binds to WNT receptors (LPR, FZD, etc.) on the cell membrane. WNT signaling is broadly divided into the WNT / β-catenin pathway (classical WNT pathway), the PCP pathway, and the Wnt / Ca pathway. 2+ In signal transduction through the WNT / β-catenin pathway, when the ligand WNT binds to the receptor, β-catenin is stabilized and accumulated in the cell and translocates to the nucleus. In the nucleus, β-catenin binds to the TCF / LEF family, resulting in transcriptional activation of target genes.
[0019] During the resting phase of hair follicles, when BMP inhibitor proteins are expressed and BMP signals are inhibited, and WNT ligands are expressed and WNT / β-catenin signals are activated, hair follicle stem cells are activated, hair follicles transition to the anagen phase, and hair elongation begins (Non-Patent Document 7). In other words, suppressing BMP signals and activating WNT signals are important for hair growth.
[0020] Proteins that inhibit the action of BMP include FST (Follistatin) and NOG (Noggin). Diphenhydramine or its salts, and glycyrrhetinic acids have the effect of promoting the production of FST, and hinokitiol has the effect of promoting the production of NOG, so that they can suppress the BMP signal through these actions and induce hair follicles into the anagen phase. On the other hand, an example of a BMP ligand is BMP2 (Bone Morphogenetic Protein 2). Glycyrrhetinic acids and hinokitiol have the effect of suppressing the production of BMP2, so that they suppress the BMP signal and activate hair follicle stem cells.
[0021] An example of a protein involved in the activation of the WNT signal is LEF1. LEF1 is a type of TCF / LEF family, Lymphoid enhancer-binding factor 1, and promotes the transmission of the WNT / β-catenin signal (transcription activation of target genes). An example of a protein that is an indicator of the activation of the WNT signal is AXIN2. AXIN2 is Axis inhibition protein 2, a type of transcription target gene of the WNT / β-catenin signal, and is considered to be an indicator of the activation of the WNT / β-catenin signal (Non-Patent Document 8). Glycyrrhetinic acids and hinokitiol have the effect of promoting the production of LEF1 and AXIN2, so they activate the WNT signal, transition the hair follicle to the anagen phase, and maintain that state. On the other hand, an example of an inhibitory protein of the WNT signal is DKK1 (Dickkopf-related protein 1). Diphenhydramine or a salt thereof and hinokitiol have the effect of suppressing the production of DKK1, thereby activating the WNT signal and promoting the proliferation of keratinocytes.
[0022] In this specification, keratinocytes include, for example, hair matrix cells, outer root sheath cells, inner root sheath cells, hair follicle stem cells, and epidermal keratinocytes. They may also be immortalized cells such as HaCaT cells, and may be of any animal species. They may also be organoids made from keratinocytes, such as three-dimensional cultured skin, or tissue culture systems containing keratinocytes taken from a living organism (hair follicles, skin, etc.).
[0023] In addition to Wnt, growth factors that contribute to hair growth include FGF2, FGF7, VEGFA, and the like (Non-Patent Document 1). Of these, substances that enhance the production of FGF2 are also effective in preventing and improving gray hair (Patent Document 1). FGF2 is fibroblast growth factor 2, also known as basic fibroblast growth factor (bFGF). FGF7 is fibroblast growth factor 7, also known as keratinocyte growth factor (KGF). VEGFA is vascular endothelial growth factor A, also known simply as VEGF. Diphenhydramine or its salts, glycyrrhetinic acids and hinokitiol have the effect of promoting the production of FGF2, glycyrrhetinic acids and hinokitiol have the effect of promoting the production of FGF7, and diphenhydramine or its salts and hinokitiol have the effect of promoting the production of VEGFA, thereby inducing and maintaining the growth phase of hair follicles.
[0024] VCAN (versican) is a type of chondroitin sulfate proteoglycan, and is specifically expressed in hair papilla cells. Substances that promote the expression of VCAN have a hair growth effect (Patent Document 2). KITL (c-Kit ligand) is also called stem cell factor, and promoting the expression of KITL in keratinocytes is effective in preventing and improving gray hair (Non-Patent Document 9). COL17A1 is a factor that constitutes the α chain of type XVII collagen. Type XVII collagen is a bell-shaped collagen that contributes to the formation of the hemidesmosome structure that connects hair follicle stem cells and hair follicles and keratinocytes of the skin to the basement membrane, and increasing the production of COL17A1 can prevent hair loss, gray hair, and skin aging due to aging (Non-Patent Documents 10, 11, 12). Glycyrrhetinic acids and hinokitiol have the effect of promoting the production of VCAN, diphenhydramine or its salts, glycyrrhetinic acids and hinokitiol have the effect of promoting the production of KITL, and diphenhydramine or its salts and hinokitiol have the effect of promoting the production of COL17A1, so through these actions, it is possible to obtain effects such as hair growth, hair care, and the prevention and improvement of gray hair.
[0025] As described above, the present invention includes a keratinocyte proliferation promoter containing diphenhydramine or its salt, glycyrrhetinic acid or hinokitiol as an active ingredient.The present invention also includes a BMP signal inhibitor based on FST, NOG production promotion or BMP2 production suppression, a WNT signal activator based on LEF1, AXIN2 production promotion or DKK1 production suppression, a FGF2, FGF7, VEGFA, VCAN, KITL and COL17A1 production promoter, and hair growth-related factor regulators such as FST production promoter, NOG production promoter, BMP2 production suppressor, LEF1 production promoter, AXIN2 production promoter and BMP2 production suppressor, which are used as the direct use of each of the above-mentioned actions.
[0026] The minoxidil metabolic activator, keratinocyte proliferation promoter, and hair growth-related factor regulator of the present invention can be provided as cosmetics, quasi-drugs, medicines, food and beverages, etc. In addition, they can also be used as reagents (positive control, etc.). The administration form is not particularly limited, but includes external use and internal use, preferably external use applied to the skin including the scalp, and particularly hair preparations applied to the scalp or hair are suitable. Examples of dosage forms for external use include lotions, liquids, creams, ointments, gels, sprays, shampoos, conditioners, soaps, etc., and examples of dosage forms for internal use include tablets, powders, powders, granules, liquids, capsules, dry syrups, jellies, liquid foods, semi-solid foods, solid foods, etc. These can be manufactured by known methods. During the manufacture, various additives that can be contained in cosmetics, quasi-drugs, medicines, food and beverages, or reagents can be blended within a range that does not impair the effects of the present invention. These cosmetics, quasi-drugs, pharmaceuticals, foods, beverages, or reagents contain at least one compound selected from the group consisting of diphenhydramine or a salt thereof, glycyrrhetinic acids, and hinokitiol as an active ingredient, and the amount of the compounded is not particularly limited, but is, for example, 0.000001 to 20% by mass in total, preferably 0.0001 to 10% by mass, and more preferably 0.01 to 1% by mass, based on the entire composition.
[0027] In addition to the above-mentioned active ingredients, the hair agent of the present invention can be used in combination with hair growth substances such as minoxidil, Swertia japonica extract, carrot extract, capsicum tincture, ginger tincture, loquat leaf extract, pantothenic acid, panthenol, vitamin E and its derivatives, salicylic acid, piroctone olamine, adenosine, t-flavanone, cytopurine, pentadecanoic acid glyceride, allantoin, and nicotinic acid amide. Among these, when minoxidil is used in combination, it can be effective for non-responders who do not fully exhibit the hair growth and hair growth effects of minoxidil due to the conversion promotion effect of diphenhydramine or its salt, glycyrrhetinic acid, and hinokitiol to minoxidil sulfate. A minoxidil non-responder is someone who does not achieve sufficient hair growth even after using minoxidil preparations for a certain period of time. The recommended period is, for example, 6 months for a 1% preparation of topical agents, and about 4 months for a 5% preparation. In addition, it is possible to predict in advance whether a person is a responder or non-responder by measuring SULT1A1 activity using pulled hair (Non-Patent Document 4), and measurement kits are also sold overseas.
[0028] In addition, the hair agent of the present invention can be labeled on a product (cosmetics, quasi-drugs, medicines, food and beverages, or reagents, etc.) or its instructions containing the hair agent to the effect that the agent is used for the purpose of each of the above-mentioned actions or uses, such as promoting keratinocyte proliferation, activating minoxidil, promoting sulfotransferase production, promoting SULT1A1 expression, suppressing BMP signaling, activating WNT signaling, or promoting VEGFA expression. Here, "labeled on the product or its instructions" means that the product body, container, packaging, etc. are labeled, or that the product information is disclosed in instructions, package inserts, promotional materials, application documents, other printed matter, or advertisements. In addition, these labels can include information on the use for preventing or treating diseases or symptoms caused by reduced keratinocyte proliferation, insufficient activation of minoxidil, reduced sulfotransferase production, reduced SULT1A1 expression, suppression of BMP signaling, activation of WNT signaling, or reduced VEGFA expression. EXAMPLES
[0029] The present invention will be described in more detail below with reference to examples and test examples, but the present invention is not limited to these examples.
[0030] (Test Example 1) Effect of each substance on keratinocyte proliferation <Test Method> Human hair follicle keratinocytes (ScienCell Research Laboratories) were cultured in a 96-well plate at 4.3 × 10 3The cells were seeded at a cell density of 10 ... <Test Results> The results of the 450 nm absorbance correction for each group are shown in Figure 1. The addition of diphenhydramine hydrochloride, glycyrrhetinic acid, or hinokitiol increased the absorbance, confirming the proliferation of keratinocytes. This confirmed that diphenhydramine hydrochloride, glycyrrhetinic acid, and hinokitiol have the effect of promoting keratinocyte proliferation.
[0031] (Test Example 2) Effect of each substance on gene expression in keratinocytes <Test Method> Human hair follicle keratinocytes (ScienCell Research Laboratories) were cultured in a 24-well plate at 2.5 × 10 4The cells were seeded at a cell density of 10 ... For comparison between groups in which homogeneity of variance could not be confirmed (the control group and the diphenhydramine hydrochloride group in FIG. 8), the Welch t-test was used. The information on the primers used in Test Examples 2 and 3 is shown in Table 1 below.
[0032] [Table 1]
[0033] <Test Results> The effect of each compound on SULT1A1 expression in hair follicle keratinocytes was evaluated, and the results are shown in Figure 2. The addition of diphenhydramine hydrochloride, glycyrrhetinic acid, or hinokitiol was confirmed to increase SULT1A1 expression. This confirmed that these compounds have the effect of promoting SULT1A1 production, the effect of promoting sulfotransferase production in hair follicle tissue, and the effect of activating the metabolism of minoxidil.
[0034] The effect of each compound on FST expression in hair follicle keratinocytes was evaluated, and the results are shown in Figure 3. The addition of diphenhydramine hydrochloride or glycyrrhetinic acid was confirmed to increase FST expression. This confirmed that these compounds have the effect of promoting FST production and suppressing BMP signals.
[0035] The effect of each compound on LEF1 expression in hair follicle keratinocytes was evaluated, and the results are shown in Figure 4. The addition of glycyrrhetinic acid or hinokitiol was confirmed to increase LEF1 expression. This confirmed that these compounds have the effect of promoting LEF1 production. The effect of each compound on AXIN2 expression in hair follicle keratinocytes was evaluated, and the results are shown in Figure 5. The addition of glycyrrhetinic acid or hinokitiol was confirmed to increase AXIN2 expression. This confirmed that these compounds have the effect of promoting AXIN2 production. The results for LEF1 and AXIN2 confirmed that glycyrrhetinic acid and hinokitiol have the effect of activating WNT signaling.
[0036] The results of evaluating the effect of each compound on FGF2 expression in hair follicle keratinocytes are shown in Figure 6. The addition of diphenhydramine hydrochloride, glycyrrhetinic acid, or hinokitiol was confirmed to increase FGF2 expression. This confirmed that these compounds have the effect of promoting FGF2 production.
[0037] The results of evaluating the effect of each compound on KITL expression in hair follicle keratinocytes are shown in Figure 7. The addition of diphenhydramine hydrochloride, glycyrrhetinic acid, or hinokitiol was confirmed to increase KITL expression. This confirmed that these compounds have the effect of promoting KITL production.
[0038] The effect of each compound on COL17A1 expression in hair follicle keratinocytes was evaluated, and the results are shown in Figure 8. The addition of diphenhydramine hydrochloride or hinokitiol was confirmed to increase COL17A1 expression. This confirmed that these compounds have the effect of promoting COL17A1 production.
[0039] (Test Example 3) Effect of each substance on gene expression in hair papilla cells <Test Method> Human hair papilla cells (Cell Applications) were seeded in a 6-well plate and cultured in a CO2 incubator (CO2 concentration 5%, temperature 37°C). MEM (Nacalai Tesque) containing 12% FBS (Thermo Fisher Scientific) and a specified amount of penicillin-streptomycin (Thermo Fisher Scientific) was used as the culture medium. After culturing until the cells were 60-70% confluent, the medium was replaced with MEM containing each substance at the desired concentration and cultured for an additional day. In some experiments, the effect of ultraviolet light was also evaluated. In these cases, ultraviolet light (UVA, 365 nm) was applied at 5 J / cm 20 hours after the MEM was replaced with MEM containing each substance at the desired concentration. 2 In both cases, 24 hours after medium replacement, RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen) according to the kit's protocol. Using this RNA as a template, cDNA was synthesized by reverse transcription using Prime Script RT Master mix (Takara Bio). From the synthesized cDNA, the expression level of the target gene mRNA was measured by the SYBR Green method using Fast SYBR Green Master Mix (Thermo Fisher Scientific) using a real-time PCR system (Step One Plus or 7500Fast, both Thermo Fisher Scientific). The expression level of the target gene was then corrected by the expression level of TBP, an internal standard gene, which was measured in the same manner. For statistical analysis, Student's t-test was used after confirming homogeneity of variance.
[0040] <Test Results> Figure 9 shows the results of evaluating the effect of each compound on NOG expression in dermal papilla cells. It was confirmed that the addition of hinokitiol increased NOG expression. It was also confirmed that NOG expression decreased with UV irradiation, and that the increase in NOG expression by the addition of hinokitiol became more pronounced under UV irradiation. This confirmed that hinokitiol has the effect of promoting NOG production. The results of evaluating the effect of each compound on BMP2 expression in hair papilla cells are shown in Figure 10. It was confirmed that the addition of glycyrrhetinic acid reduced BMP2 expression. It was also confirmed that BMP2 expression was increased by UV irradiation, that the reduction in BMP2 expression by the addition of glycyrrhetinic acid was more significant under UV irradiation, and that hinokitiol also reduced BMP2 expression. From these results, it was confirmed that glycyrrhetinic acid and hinokitiol have an inhibitory effect on BMP2 production. The NOG and BMP2 results confirmed that glycyrrhetinic acid and hinokitiol have an inhibitory effect on BMP signaling.
[0041] The results of evaluating the effect of each compound on FGF2 expression in dermal papilla cells are shown in Figure 11. An increase in FGF2 expression was confirmed by the addition of glycyrrhetinic acid or hinokitiol. This confirmed that these compounds have the effect of promoting FGF2 production. The results of evaluating the effect of each compound on FGF7 expression in dermal papilla cells are shown in Figure 12. Increased expression of FGF7 was confirmed by the addition of glycyrrhetinic acid or hinokitiol. This confirmed that these compounds have the effect of promoting FGF7 production. FIG. 13 shows the results of evaluating the effect of each compound on VEGFA expression in dermal papilla cells. An increase in VEGFA expression was confirmed by the addition of diphenhydramine hydrochloride or hinokitiol. This confirmed that these compounds have the effect of promoting VEGFA expression. FIG. 14 shows the results of evaluating the effect of each compound on VCAN expression in dermal papilla cells. An increase in VCAN expression was confirmed by the addition of glycyrrhetinic acid or hinokitiol. It was also confirmed that VCAN expression was reduced by ultraviolet irradiation, and that the increase in VCAN expression by the addition of glycyrrhetinic acid was more significant under ultraviolet irradiation. This confirmed that glycyrrhetinic acid and hinokitiol have the effect of promoting VCAN production. The results of evaluating the effect of each compound on DKK1 expression in dermal papilla cells are shown in Figures 15 and 16. The addition of diphenhydramine hydrochloride or hinokitiol was confirmed to decrease DKK1 expression. This confirmed that these compounds have an inhibitory effect on DKK1 production and an activation effect on WNT signaling. [Industrial Applicability]
[0042] The hair care agent of the present invention can be used in the fields of cosmetics, quasi-drugs, pharmaceuticals, or food and beverages to promote or support hair growth through promotion of keratinocyte proliferation, activation of the metabolism of minoxidil, and the like.
Claims
1. A metabolic activator of minoxidil, containing diphenhydramine or its salt as the active ingredient.
2. The metabolic activator of minoxidil according to claim 1, which is based on the promoting effect of its conversion to minoxidil sulfate.
3. The metabolic activator of minoxidil according to claim 1, which is based on the effect of promoting the production of sulfotransferase.
4. The metabolic activator of minoxidil according to claim 1, which is based on the effect of promoting the production of SULT1A1.
Citation Information
Patent Citations
Hair growing composition
JP2002326913A
Hair tonic and hair growth agent composition
JP2006160652A
Hair growing agent composition
JP2007022919A
Hair and scalp detergent, percutaneous absorption accelerator and percutaneous absorption accelerating method
JP2007031376A
Hair grower
JP2009108023A
